The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition?

by Philippe Van Wilder
Published 2021-04-01

The impact of early phase price agreements on prices of orphan drugs

by Mark Nuijten, Philippe Van Wilder
Published 2021-03-01

Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Diso...

by Philippe van Wilder, Irina Odnoletkova, Mehdi Mouline, Esther de Vries
Published 2021-01-01

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations

by Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Isabelle Huys
Published 2021-02-01

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis

by Yannick Vandenplas, Steven Simoens, Philippe Van Wilder, Arnold G. Vulto, Arnold G. Vulto, Isabelle Huys
Published 2021-04-01

The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data

by Irina Odnoletkova, Gerhard Kindle, Isabella Quinti, Bodo Grimbacher, Viviane Knerr, Benjamin Gathmann, Stephan Ehl, Nizar Mahlaoui, Philippe Van Wilder, Kris Bogaerts, Esther de Vries, in collaboration with the Plasma Protein Therapeutics Association (PPTA) Taskforce
Published 2018-11-01